Status:
UNKNOWN
COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma
Lead Sponsor:
Centro de Hematología y Medicina Interna
Collaborating Sponsors:
Laboratorios Clínicos de Puebla (Laboratorios Ruiz)
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
COVID-19 disease has become a very serious global health problem. Treatments for severe forms are urgently needed to lower mortality. Any procedure that improves these forms should be considered, espe...
Eligibility Criteria
Inclusion
- Patients with SARS-CoV2 infection who have had a serious evolution and are in an ICU
- With or without ventilatory assistance
- Treated or not with hydroxychloroquine 200 mg. every 12 hours
- Indistinct sex
- Older than 18 years
- Signed informed consent
Exclusion
- Patients treated with the following medications: azithromycin, ritonavir / lopinavir, remdesivir, interferons, ruxolinitib, tocilizumab.
- Patients with severe kidney failure who require replacement therapy.
Key Trial Info
Start Date :
April 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04357106
Start Date
April 13 2020
End Date
August 1 2020
Last Update
April 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro de Hematología y Medicina Interna
Puebla City, Mexico, 72530